Dimerix (ASX:DXB) is a clinical-stage biopharmaceutical company with a portfolio of drug candidates for inflammatory diseases, including kidney and respiratory diseases. Dimerix’ lead clinical asset, DMX-200 (or QYTOVRA® in some territories), is in Phase 3 trials as a treatment for focal segmental g...See more
Headquarters:
Australia
Company Type:
MNC / Large Enterprise
Company size:
1-10 Employees
Address:
MELBOURNE, VICTORIA 3000, AU
LOW
spending power
